Difamilast demonstrated safety, efficacy in multiple eczema trials, joins crisaborole, rof ...

By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc.

Treatment approaches have shifted with the introduction of targeted agents, notably Bruton tyrosine kinase (BTK) inhibitors, as well as the emerging role of immunotherapy, according to a new review ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

The FDA accepted filing for a new drug application (NDA) today for tirabrutinib for the treatment of adults with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL), according ...

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns overshadowing the drug class. The biopharma, which markets Novartis-partnered ...

Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...

Treatment with a JAK inhibitor should be standard of care for any patient with alopecia areata who desires it, even if their hair loss is less than 50%, according to a speaker at South Beach Symposium ...

U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated ...